We are snap-polling oncologists to gauge reaction to detailed results from the Phase III EMERALD study evaluating Radius Heath and Menarini’s oral SERD elacestrant for the treatment of ER-positive/HER2-negative breast cancer, which were presented this week at the San Antonia Breast Cancer Symposium (SABCS).
The results for elacestrant are notable as they pre-empt the readout of pivotal-stage data from similar studies for oral SERDs being developed by larger players in AstraZeneca, Roche and Sanofi next year.
Specifically we are asking oncologists
Poll results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers.
To read more Physician Views articles, click here.